Kristen Hurley
Director Medical Affairs Kite Pharma Inc
Seminars
Wednesday 15th July 2026
Fireside Chat: Delivering Expanded Access for High-Complexity and One-Time Therapies
4:15 pm
- How do companies practically operationalize Expanded Access Programs for cell and gene therapies?
- What factors most often determine feasibility when manufacturing constraints, logistics, and cost are extreme?
- How do organizations assess when expanded access is realistic – and when it risks creating false hope for patients and providers?
- How can regulatory incentives and long-term development strategy be thoughtfully integrated into Expanded Access decision-making?
